



DKT. 30436.11US06/SBA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 05 2002

TECH CENTER 1600/2900

Applicants : Peter S. Linsley et al.
Serial No : 09/666,267
Filed : September 21, 2000
For : LIGAND FOR CD28 RECEPTOR ON B CELLS AND
METHODS

55 S. Lake Avenue, Suite 710
Pasadena, California 91101
September 23, 2002


Assistant Commissioner for Patents
Box Sequence
Arlington, VA 22202

SIR:

DECLARATION PURSUANT TO 37 C.F.R. §1.821(f)

I hereby declare that the content of the paper and computer readable copies of the Sequence Listings, submitted in the subject patent application in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same. The sequence listing contains no new matter pursuant to 37 C.F.R. 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d), and is supported by the specification as originally filed.

Respectfully submitted,


Renato Marco P. Domingo

BEST AVAILABLE COPY



30436.11US06/SBA/TYL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Peter S. Linsley et al.
Serial No. : 09/666,267 Examiner: P. Gambel
Filed : September 21, 2000 Group Art Unit: 1644
For : LIGAND FOR CD28 RECEPTOR ON B CELLS AND METHODS

55 S. Lake Avenue, Suite 710
Pasadena, California 91101

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

DECLARATION
UNDER MPEP § 608.01(p)

I hereby declare that the amendatory material submitted herewith, which is the predicted amino acid sequence of amino acids 1-216 of human B7 as published on page 2717 by Freeman, G.J. et al. in "B7, A New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic Cells", J. of Immunology, 143(8), 2714-2722, 1989, consists of the same material incorporated by reference in the above-referenced application (U.S. Serial No. 09/666,267).

9/23/02

DATE

Teresa Liang

Teresa Y. Liang, Ph.D.
Registration No. 51,946

BEST AVAILABLE COPY



American Type Culture Collection

12301 Parklawn Drive • Rockville, MD 20852 USA • Telephone: (301) 231-5524 Telex: 894 455 ATCCNORTH • FAX: (301) 770-2547

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2
To: (Name and Address of Depositor or Attorney)

Bristol-Myers Squibb Company
Attention: Peter Lineley
3005 First Avenue
Seattle, WA 98121

Deposited on Behalf of: Bristol-Myers Squibb Company

Identification Reference by Depositor:

ATCC Designation

<u>Escherichia coli</u> MC1081/P3 with plasmid, B7lg	68627
<u>Escherichia coli</u> MC1081/P3 with plasmid, CD28lg	68628
<u>Escherichia coli</u> MC1081/P3 with plasmid, CTLA4lg	68629

The deposits were accompanied by: ☐ a scientific description ☒ a proposed taxonomic description indicated above.

The deposits were received May 31, 1991 by this International Depository Authority and have been accepted.

AT YOUR REQUEST:

☒ We will inform you of requests for the strains for 30 years.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strains.

If the cultures should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace them with living cultures of the same.

The strains will be maintained for a period of at least 30 years after the date of deposit, and for a period of at least five years after the most recent request for a sample. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the cultures cited above was tested June 4, 1991. On that date, the cultures were viable.

International Depository Authority: American Type Culture Collection, Rockville, Md. 20852 USA

Signature of person having authority to represent ATCC:

Bobbie A. Brandon
Bobbie A. Brandon, Head, ATCC Patent Depository

Date: June 8, 1991

cc: Brian W. Poor ✓